ReviewCancers2023
New Treatment Options in Metastatic Pancreatic Cancer.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Desmoplasia and therapeutic resistance in pancreatic ductal adenocarcinoma.Cancer letters · 2026Review
- Dual-Targeting iRGD-Functionalized Pentablock Copolymer Nanosystem for miR-345-5p and Gemcitabine Delivery to Pancreatic Tumors.ACS applied materials & interfaces · 2026Article
- Excellent Survival Outcome in a Patient Receiving NALIRIFOX for Metastatic Pancreatic Adenocarcinoma: A Case Report.Oncology research · 2026Article
- Review
- Article
- Review
- An 81-Year-Old Geriatric Patient with Metastatic Pancreatic Cancer Demonstrating Excellent Response and Well Tolerance to NALIRIFOX: A Case Report and Literature Review.Reports (MDPI) · 2025Article
- Review
- Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now?Cancers · 2025Review
- Power-Doppler-based NH002 microbubble sonoporation with chemotherapy relieves hypoxia and enhances the efficacy of chemotherapy and immunotherapy for pancreatic tumors.Scientific reports · 2024Article
- Review
- Chimeric Antigen Receptor T Cell Therapy for Pancreatic Cancer: A Review of Current Evidence.Cells · 2024Review
- Review
- Management of Metastatic Pancreatic Cancer-Comparison of Global Guidelines over the Last 5 Years.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is the seventh leading cause of cancer death across the world. Poor prognosis of PC is associated with several factors, such as diagnosis at an advanced stage, early distant metastases, and remarkable resistance to most conventional treatment options. The pathogenesis of PC seems to be significantly more complicated than originally assumed, and findings in other solid tumours cannot be extrapolated to this malignancy. To develop effective treatment schemes prolonging patient survival, a multidirectional approach encompassing different aspects of the cancer is needed. Particular directions have been established; however, further studies bringing them all together and connecting the strengths of each therapy are needed. This review summarises the current literature and provides an overview of new or emerging therapeutic strategies for the more effective management of metastatic PC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.